PCVX FINANCIAL STATEMENTS

Vaxcyte Inc — balance sheet, income statement and cash flow trends

PCVXVaxcyte Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue0 $—

Gross Profit-5.9 M $—

Operating Income-1.1 B $—

EBITDA-920.7 M $—

Net Income-946.5 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PCVX	—	—	—	—
TLX	56.3%	50.8%	3.0%	-0.9%
CSL	4.8%	48.6%	32.8%	9.2%
MSB	410.4%	-32.0%	-76.6%	-115.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PCVX	—	—	—	—
IMVT	-100.0%	—	—	—
TGTX	81.3%	83.0%	21.4%	66.0%
RYTM	58.7%	89.4%	-83.2%	-93.3%
MIRM	50.2%	81.4%	-133.6%	-140.2%
SMMT	—	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity3 B $89%
Current Liabilities242.1 M $7%
Long-term Liabilities110.2 M $3%

Key Figures

YoY change

Total Assets3.3 B $-0.9%

Total Liabilities352.3 M $+97.8%

Total Equity3 B $-6.4%

Cash & ST Investments1.7 B $+3.9%

Total Debt116.3 M $+33.4%

Net Debt-144.5 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PCVX	7.49	3.9%	1.76	89.5%
TLX	1.43	112.3%	13.13	35.1%
CSL	2.57	67.4%	2.22	49.2%
MSB	—	—	—	—
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PCVX	7.49	3.9%	1.76	89.5%
IMVT	9.09	0.0%	1.79	89.1%
TGTX	5.81	129.2%	1.59	38.1%
RYTM	4.17	184.7%	0.63	27.8%
MIRM	2.09	133.5%	0.08	27.2%
SMMT	7.41	3.7%	0.69	84.3%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-769.9 M $—

Capital Expenditures51.9 M $-63.0%

Free Cash Flow-771.7 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PCVX	—	—	—	81.3%
TLX	-2.2%	-6.3%	4.1%	243.1%
CSL	24.0%	20.3%	3.7%	261.5%
MSB	-87.7%	-90.0%	2.3%	76.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PCVX	—	—	—	81.3%
IMVT	—	—	—	80.6%
TGTX	-2.0%	-2.0%	0.0%	-3.0%
RYTM	-55.0%	-55.5%	0.4%	59.0%
MIRM	-30.0%	-30.3%	0.3%	21.4%
SMMT	—	—	—	37.9%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PCVX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.